Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced it has completed enrollment in its first pivotal Phase 3 clinical trial, COVE-2, evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA